Short Interest in Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Drops By 42.7%

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) saw a significant decline in short interest in December. As of December 15th, there was short interest totaling 40,499 shares, a decline of 42.7% from the November 30th total of 70,734 shares. Currently, 5.6% of the company’s stock are short sold. Based on an average daily volume of 130,184 shares, the days-to-cover ratio is currently 0.3 days. Based on an average daily volume of 130,184 shares, the days-to-cover ratio is currently 0.3 days. Currently, 5.6% of the company’s stock are short sold.

Insider Buying and Selling at Quoin Pharmaceuticals

In other news, Director Dennis Langer bought 15,152 shares of Quoin Pharmaceuticals stock in a transaction dated Tuesday, October 14th. The shares were acquired at an average cost of $8.49 per share, with a total value of $128,640.48. Following the completion of the transaction, the director owned 15,153 shares in the company, valued at approximately $128,648.97. This trade represents a 1,515,200.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 13.46% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a report on Monday, December 22nd. Wall Street Zen raised shares of Quoin Pharmaceuticals to a “sell” rating in a research report on Saturday, November 15th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Quoin Pharmaceuticals currently has an average rating of “Sell”.

Quoin Pharmaceuticals Stock Performance

Shares of NASDAQ QNRX traded up $0.09 during midday trading on Friday, hitting $13.99. The company’s stock had a trading volume of 11,444 shares, compared to its average volume of 93,389. Quoin Pharmaceuticals has a 1-year low of $5.01 and a 1-year high of $41.80. The firm’s fifty day moving average price is $14.32 and its 200-day moving average price is $10.50. The firm has a market cap of $11.75 million, a P/E ratio of -0.44 and a beta of 1.59.

Quoin Pharmaceuticals (NASDAQ:QNRX) last issued its earnings results on Thursday, November 6th. The company reported ($6.71) EPS for the quarter, missing analysts’ consensus estimates of ($6.36) by ($0.35). As a group, research analysts predict that Quoin Pharmaceuticals will post -2.05 earnings per share for the current fiscal year.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.